T1	PROC 45 86	Ensayo en fase III, abierto, aleatorizado
T2	CHEM 91 102	carfilzomib
#1	AnnotatorNotes T2	C2001856; carfilzomib; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T3	CHEM 104 112	melfalán
#2	AnnotatorNotes T3	C0025241; melphalan; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T4	CHEM 115 125	prednisona
#3	AnnotatorNotes T4	C0032952; prednisone; Hormone · Organic Chemical · Pharmacologic Substance
T5	CHEM 135 145	bortezomib
#4	AnnotatorNotes T5	C1176309; bortezomib; Organic Chemical · Pharmacologic Substance
T6	CHEM 147 155	melfalán
#5	AnnotatorNotes T6	C0025241; melphalan; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T7	CHEM 158 168	prednisona
#6	AnnotatorNotes T7	C0032952; prednisone; Hormone · Organic Chemical · Pharmacologic Substance
T8	PROC 196 206	trasplante
#7	AnnotatorNotes T8	C0040732; Transplantation; Therapeutic or Preventive Procedure
T9	DISO 211 227	mieloma múltiple
#8	AnnotatorNotes T9	C0026764; Multiple Myeloma; Neoplastic Process
T10	PROC 237 248	diagnóstico
#9	AnnotatorNotes T10	C0011900; Diagnosis; Diagnostic Procedure
T11	DISO 270 286	Mieloma múltiple
#10	AnnotatorNotes T11	C0026764; Multiple Myeloma; Neoplastic Process
T12	DISO 312 340	Mieloma múltiple sintomático
T13	PROC 350 361	diagnóstico
#11	AnnotatorNotes T13	C0011900; Diagnosis; Diagnostic Procedure
T14	PROC 384 394	trasplante
#12	AnnotatorNotes T14	C0040732; Transplantation; Therapeutic or Preventive Procedure
T15	PROC 431 473	Fracción de eyección ventricular izquierda
T16	PROC 475 479	FEVI
#13	AnnotatorNotes T16	C2114363; left ventricular ejection fraction assessment; Therapeutic or Preventive Procedure
T17	DISO 512 526	Síndrome POEMS
#14	AnnotatorNotes T17	C0085404; POEMS Syndrome; Disease or Syndrome
T18	DISO 528 542	polineuropatía
#15	AnnotatorNotes T18	C0152025; Polyneuropathy; Disease or Syndrome
T19	DISO 559 573	endocrinopatía
#16	AnnotatorNotes T19	C0014130; Endocrine System Diseases; Disease or Syndrome
T20	CHEM 575 594	proteína monoclonal
#17	AnnotatorNotes T20	C0443737; Monoclonal immunoglobulin; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T21	DISO 597 618	alteraciones cutáneas
T22	DISO 620 651	Leucemia de células plasmáticas
#18	AnnotatorNotes T22	C0023484; Leukemia, Plasma Cell; Neoplastic Process
T23	DISO 686 688	WM
T24	DISO 652 684	Macroglobulinemia de Waldenström
#19	AnnotatorNotes T24	C0024419; Waldenstrom Macroglobulinemia; Neoplastic Process
T25	DISO 690 701	Amiloidosis
#20	AnnotatorNotes T25	C0002726; Amyloidosis; Disease or Syndrome | C0011560; Amyloid deposition; Disease or Syndrom
T26	DISO 711 721	Neuropatía
#21	AnnotatorNotes T26	C0442874; Neuropathy; Disease or Syndrome
T27	PROC 782 796	aleatorización
#22	AnnotatorNotes T27	C0034656; Randomization; Research Activity
T28	ANAT 452 463	ventricular
#23	AnnotatorNotes T28	C0018827; Heart Ventricle; Body Part, Organ, or Organ Component | C1280934; Entire cardiac ventricle; Body Part, Organ, or Organ Component
T29	DISO 544 557	organomegalia
#24	AnnotatorNotes T29	C4054315; Organomegaly; Finding
T30	ANAT 610 618	cutáneas
#25	AnnotatorNotes T30	C0011646; Dermis; Tissue | C1123023; Skin; Body System
T31	ANAT 632 651	células plasmáticas
#26	AnnotatorNotes T31	C0032112; Plasma Cells; Cell
T32	Date 13 17	2012
T33	LIVB 172 181	pacientes
#27	AnnotatorNotes T33	C0030705; Patients; Patient or Disabled Group
T34	Neg_cue 182 184	no
T35	LIVB 362 370	Paciente
#28	AnnotatorNotes T35	C0030705; Patients; Patient or Disabled Group
T36	Neg_cue 371 373	no
T37	LIVB 405 412	mujeres
#29	AnnotatorNotes T37	C0043210; Woman; Population Group
T38	Age 421 430	≥ 18 años
T39	Duration 757 768	los 14 días
T40	PHYS 443 473	eyección ventricular izquierda
#30	AnnotatorNotes T40	C2733342; Left ventricular ejection; Physiologic Function
T41	LIVB 395 402	Varones
#31	AnnotatorNotes T41	C0025266; Male population group; Population Group
A1	Assertion T8 Negated
A2	Assertion T14 Negated
A3	Status T25 History_of
A4	Status T26 History_of
#32	AnnotatorNotes T1	C0282461; Phase 3 Clinical Trials; Research Activity + C1709323; Open Label Study; Research Activity + C0034656; Randomization; Research Activity
#33	AnnotatorNotes T15	C2114363; left ventricular ejection fraction assessment; Therapeutic or Preventive Procedure
#34	AnnotatorNotes T21	C0946387; Skin Integrity Alteration; Finding | C1820722; Alterations in skin; Finding
#35	AnnotatorNotes T23	C0024419; Waldenstrom Macroglobulinemia; Neoplastic Process
R1	Combined_with Arg1:T2 Arg2:T3	
R2	Combined_with Arg1:T3 Arg2:T4	
R3	Combined_with Arg1:T5 Arg2:T6	
R4	Combined_with Arg1:T6 Arg2:T7	
R5	Experiences Arg1:T33 Arg2:T2	
R6	Experiences Arg1:T33 Arg2:T5	
R7	Experiences Arg1:T33 Arg2:T8	
R8	Negation Arg1:T34 Arg2:T8	
T42	Quantifier_or_Qualifier 231 248	nuevo diagnóstico
#36	AnnotatorNotes T42	C1518321; Newly Diagnosed; Qualitative Concept
T43	Quantifier_or_Qualifier 344 361	nuevo diagnóstico
#37	AnnotatorNotes T43	C1518321; Newly Diagnosed; Qualitative Concept
R11	Experiences Arg1:T33 Arg2:T9	
R9	Has_Quantifier_or_Qualifier Arg1:T9 Arg2:T42	
R10	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T43	
R12	Negation Arg1:T36 Arg2:T14	
R13	Experiences Arg1:T35 Arg2:T14	
R14	Has_Age Arg1:T37 Arg2:T38	
R15	Has_Age Arg1:T41 Arg2:T38	
R16	Location_of Arg1:T28 Arg2:T40	
R17	Location_of Arg1:T28 Arg2:T15	
R18	Location_of Arg1:T28 Arg2:T16	
T44	Result_or_Value 481 486	≥ 40%
R21	Has_Result_or_Value Arg1:T16 Arg2:T44	
R22	Has_Result_or_Value Arg1:T15 Arg2:T44	
R23	Overlap Arg1:T18 Arg2:T29	
R24	Overlap Arg1:T29 Arg2:T19	
R25	Overlap Arg1:T19 Arg2:T20	
R26	Overlap Arg1:T20 Arg2:T21	
R27	Location_of Arg1:T30 Arg2:T21	
R28	Location_of Arg1:T31 Arg2:T22	
T45	Quantifier_or_Qualifier 737 747	Grados ≥ 2
R29	Has_Quantifier_or_Qualifier Arg1:T26 Arg2:T45	
R30	Has_Duration_or_Interval Arg1:T26 Arg2:T39	
R31	Before Arg1:T26 Arg2:T27	
T46	Quantifier_or_Qualifier 722 735	significativa
#38	AnnotatorNotes T46	C1546944; Event Seriousness - Significant; Qualitative Concept
R32	Has_Quantifier_or_Qualifier Arg1:T26 Arg2:T46	
A5	Experiencer T33 Patient
A6	Experiencer T35 Patient
A7	Experiencer T41 Patient
A8	Experiencer T37 Patient
